Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Neil Stahl sold 8,306 shares of the business’s stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $532.55, for a total value of $4,423,360.30. Following the sale, the executive vice president now owns 43,950 shares of the company’s stock, valued at $23,405,572.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Neil Stahl also recently made the following trade(s):
- On Thursday, June 15th, Neil Stahl sold 8,567 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $468.45, for a total value of $4,013,211.15.
- On Friday, June 2nd, Neil Stahl sold 2,812 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $479.49, for a total value of $1,348,325.88.
Shares of Regeneron Pharmaceuticals, Inc. (REGN) opened at 515.91 on Tuesday. Regeneron Pharmaceuticals, Inc. has a one year low of $325.35 and a one year high of $521.51. The stock has a market capitalization of $54.47 billion, a PE ratio of 62.45 and a beta of 1.53. The stock’s 50 day moving average price is $456.19 and its 200 day moving average price is $393.90.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.50 by $0.42. The company had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.30 billion. Regeneron Pharmaceuticals had a return on equity of 22.99% and a net margin of 19.34%. The firm’s revenue for the quarter was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post $12.68 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was published by Mideast Time and is the sole property of of Mideast Time. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.mideasttime.com/neil-stahl-sells-8306-shares-of-regeneron-pharmaceuticals-inc-regn-stock/1813336.html.
A number of research firms have issued reports on REGN. BMO Capital Markets boosted their price target on Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a “hold” rating in a research note on Monday, May 15th. Vetr downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $408.86 price target for the company. in a research note on Monday, April 24th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 14th. Canaccord Genuity set a $484.00 price target on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, June 20th. Finally, Cowen and Company restated a “hold” rating and set a $380.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, May 15th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $446.41.
Institutional investors have recently added to or reduced their stakes in the company. Grandfield & Dodd LLC raised its position in Regeneron Pharmaceuticals by 1.1% in the first quarter. Grandfield & Dodd LLC now owns 1,497 shares of the biopharmaceutical company’s stock worth $580,000 after buying an additional 17 shares during the period. Opus Point Partners Management LLC raised its position in Regeneron Pharmaceuticals by 2.3% in the fourth quarter. Opus Point Partners Management LLC now owns 7,684 shares of the biopharmaceutical company’s stock worth $2,821,000 after buying an additional 172 shares during the period. Highbridge Capital Management LLC bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth $323,000. Princeton Capital Management Inc. raised its position in Regeneron Pharmaceuticals by 6.7% in the first quarter. Princeton Capital Management Inc. now owns 2,496 shares of the biopharmaceutical company’s stock worth $967,000 after buying an additional 157 shares during the period. Finally, CIBC World Markets Inc. raised its position in Regeneron Pharmaceuticals by 2,190.6% in the first quarter. CIBC World Markets Inc. now owns 21,784 shares of the biopharmaceutical company’s stock worth $8,442,000 after buying an additional 20,833 shares during the period. 66.90% of the stock is currently owned by institutional investors.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.